Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.

Pharmacopsychiatry - 1 Jan 2000

Lohmann P L, Bagli M, Krauss H, Müller D J, Schulze T G, Fangerau H, Ludwig M, Barkow K, Held T, Heun R, Maier W, Rietschel M, Rao M L

Abstract excerpt

Antipsychotic drug-induced tardive dyskinesia (TD) is a serious problem during psychopharmacologic treatment of schizophrenic patients. In search of genetic factors contributing to TD, there is a lack of consensus regarding the role of the polymorphic isozyme cytochrome P450 CYP2D6, which is invo...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dyskinesia, Drug-Induced

Share to Genotype

Share to Polymorphism, Genetic

Share to Schizophrenia

Source

Identifiers

PMID: 12734765
DOI: 10.1055/s-2003-39048

Genes

CPZ

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-12734765-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.PMID 12734765Read ↗

Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia.Semantic proximity Read ↗

Association of tardive dyskinesia with variation in CYP2D6: Is there a role for active metabolites?Semantic proximity Read ↗

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.Semantic proximity Read ↗

Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics.Semantic proximity Read ↗

Non-functional CYP2D6 alleles and risk for neuroleptic-induced movement disorders in schizophrenic patients.Semantic proximity Read ↗

Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients.Semantic proximity Read ↗

CYP 2D6 polymorphism and antipsychotic therapy.Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

Genetics of tardive dyskinesia.Semantic proximity Read ↗

CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects.Semantic proximity Read ↗

Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients.Semantic proximity Read ↗

Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.